» Articles » PMID: 35215767

Targeting the Virus Capsid As a Tool to Fight RNA Viruses

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Feb 26
PMID 35215767
Authors
Affiliations
Soon will be listed here.
Abstract

Several strategies have been developed to fight viral infections, not only in humans but also in animals and plants. Some of them are based on the development of efficient vaccines, to target the virus by developed antibodies, others focus on finding antiviral compounds with activities that inhibit selected virus replication steps. Currently, there is an increasing number of antiviral drugs on the market; however, some have unpleasant side effects, are toxic to cells, or the viruses quickly develop resistance to them. As the current situation shows, the combination of multiple antiviral strategies or the combination of the use of various compounds within one strategy is very important. The most desirable are combinations of drugs that inhibit different steps in the virus life cycle. This is an important issue especially for RNA viruses, which replicate their genomes using error-prone RNA polymerases and rapidly develop mutants resistant to applied antiviral compounds. Here, we focus on compounds targeting viral structural capsid proteins, thereby inhibiting virus assembly or disassembly, virus binding to cellular receptors, or acting by inhibiting other virus replication mechanisms. This review is an update of existing papers on a similar topic, by focusing on the most recent advances in the rapidly evolving research of compounds targeting capsid proteins of RNA viruses.

Citing Articles

Investigation of small molecules disrupting dengue virus assembly by inhibiting capsid protein and blocking RNA encapsulation.

Panday H, Jha A, Dwivedi V Mol Divers. 2024; .

PMID: 39304568 DOI: 10.1007/s11030-024-10980-z.


New Copper Complexes with N,O-Donor Ligands Based on Pyrazole Moieties Supported by 3-Substituted Acetylacetone Scaffolds.

Del Gobbo J, Santini C, Dolmella A, Li Z, Caviglia M, Pellei M Molecules. 2024; 29(3).

PMID: 38338366 PMC: 10856362. DOI: 10.3390/molecules29030621.


Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.

Rahman A, Roy K, Deb G, Ha T, Rahman S, Aktar M Int J Mol Sci. 2023; 24(17).

PMID: 37685938 PMC: 10488153. DOI: 10.3390/ijms241713130.

References
1.
Ganser B, Li S, Klishko V, Finch J, Sundquist W . Assembly and analysis of conical models for the HIV-1 core. Science. 1999; 283(5398):80-3. DOI: 10.1126/science.283.5398.80. View

2.
Boson B, Denolly S, Turlure F, Chamot C, Dreux M, Cosset F . Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites. Gastroenterology. 2016; 152(4):895-907.e14. DOI: 10.1053/j.gastro.2016.11.047. View

3.
Ren P, Zheng Y, Wang W, Hong L, Delpeyroux F, Arenzana-Seisdedos F . Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci Rep. 2017; 7:42902. PMC: 5317167. DOI: 10.1038/srep42902. View

4.
Kim J, Jung Y, Kim C, Shin J, Scheers E, Lee J . A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. J Med Chem. 2017; 60(13):5472-5492. DOI: 10.1021/acs.jmedchem.7b00175. View

5.
Lee Y, Cha H, Hwang J, Park S, Vishakantegowda A, Imran A . Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Med Chem Lett. 2021; 12(2):242-248. PMC: 7883466. DOI: 10.1021/acsmedchemlett.0c00606. View